Pasireotide is under clinical development by Recordati and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pasireotide’s likelihood of approval (LoA) and phase transition for Follicular Thyroid Cancer took place on 27 Oct 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 27 Oct 2020 increased Pasireotide’s LoA and PTSR for Medullary Thyroid Cancer, and increased LoA and PTSR for Papillary Thyroid Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pasireotide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pasireotide overview

Pasireotide (Signifor, Upelior) is a synthetic polypeptide analogue of somatostatin. It is formulated as injectable solution and powder for suspension for subcutaneous route of administration. Pasireotide is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.

Pasireotide is under development for the treatment of medullary thyroid cancer, papillary thyroid cancer, metastatic liver cancer and follicular thyroid cancer. It was also under development for Nelson syndrome, fistula, meningioma, leak, cluster headache, dumping syndrome, hepatocellular carcinoma, hypoglycemia, metastatic hepatocellular carcinoma, abscess and carcinoid tumors including neuroendocrine gastroenteropancreatic tumors. It was also under development for the treatment of  unresectable neuroendocrine hepatic metastases

Recordati overview

Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.

Quick View Pasireotide LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Pasireotide
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Hormonal Disorders
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
Key Developers
  • Sponsor Company: Recordati
  • Originator: Novartis
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.